Mycobacterium tuberculosis ribosomal protein S1 (RpsA) and variants with truncated C-terminal end show absence of interaction with pyrazinoic acid.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
20 05 2020
Historique:
received: 23 12 2019
accepted: 29 04 2020
entrez: 21 5 2020
pubmed: 21 5 2020
medline: 15 12 2020
Statut: epublish

Résumé

Pyrazinamide (PZA) is an antibiotic used in first- and second-line tuberculosis treatment regimens. Approximately 50% of multidrug-resistant tuberculosis and over 90% of extensively drug-resistant tuberculosis strains are also PZA resistant. Despite the key role played by PZA, its mechanisms of action are not yet fully understood. It has been postulated that pyrazinoic acid (POA), the hydrolyzed product of PZA, could inhibit trans-translation by binding to Ribosomal protein S1 (RpsA) and competing with tmRNA, the natural cofactor of RpsA. Subsequent data, however, indicate that these early findings resulted from experimental artifact. Hence, in this study we assess the capacity of POA to compete with tmRNA for RpsA. We evaluated RpsA wild type (WT), RpsA ∆A438, and RpsA ∆A438 variants with truncations towards the carboxy terminal end. Interactions were measured using Nuclear Magnetic Resonance spectroscopy (NMR), Isothermal Titration Calorimetry (ITC), Microscale Thermophoresis (MST), and Electrophoretic Mobility Shift Assay (EMSA). We found no measurable binding between POA and RpsA (WT or variants). This suggests that RpsA may not be involved in the mechanism of action of PZA in Mycobacterium tuberculosis, as previously thought. Interactions observed between tmRNA and RpsA WT, RpsA ∆A438, and each of the truncated variants of RpsA ∆A438, are reported.

Identifiants

pubmed: 32433489
doi: 10.1038/s41598-020-65173-z
pii: 10.1038/s41598-020-65173-z
pmc: PMC7239899
doi:

Substances chimiques

Antitubercular Agents 0
Bacterial Proteins 0
RNA, Bacterial 0
Ribosomal Proteins 0
ribosomal protein S1 0
tmRNA 0
Pyrazinamide 2KNI5N06TI
pyrazinoic acid 2WB23298SP

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8356

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P019978/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P019978/2
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 099805/Z/12/Z
Pays : United Kingdom

Références

World Health Organization. Global Tuberculosis Report. Multidrug./rifampicin-resistant TB(MDR/RR-TB): Update 2017, www.who.int/tb/areas-of-work/drug-resistant-tb/MDR_TB_2017.pdf?ua=1 (2017).
World Health Organization. Directrices sobre la atención de la infección tuberculosa latente, https://apps.who.int/iris/bitstream/handle/10665/137336/9789243548906_spa.pdf;jsessionid=A5454A7B7C71AFF94FC57DB99E687E34?sequence=1 (2015).
Comstock, G. W., Livesay, V. T. & Woolpert, S. F. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol, 99(2), 131–8., https://academic.oup.com/aje/article/162081/THE (1974).
Sloot, R., Schim van der Loeff, M. F., Kouw, P. M. & Borgdorff, M. W. Risk of Tuberculosis after Recent Exposure. A 10-Year Follow-up Study of Contacts in Amsterdam. Am J Respir Crit Care Med. 190(9), 1044–52, https://doi.org/10.1164/rccm.201406-1159OC (2014).
pubmed: 25265362 doi: 10.1164/rccm.201406-1159OC
Singapore Tuberculosis Service/British Medical Research Council. Five- Year Follow-Up of a Clinical Trial of Three 6-Month Regimens of Chemotherapy Given Intermittently in the Continuation Phase in the Treatment of Pulmonary Tuberculosis 1- 3. Am. Rev. Respir. Dis. 137(5), 1147–50 (1988).
doi: 10.1164/ajrccm/137.5.1147
Zhang, Y., Scorpio, A., Nikaido, H. & Sun, Z. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Bacteriol.. 181(7), 2044–9, http://www.ncbi.nlm.nih.gov/pubmed/10094680 (1999).
Zhang, Y., Wade, M., Scorpio, A., Zhang, H. & Sun, Z. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother. 52(5), 790–5, https://doi.org/10.1093/jac/dkg446 (2003).
pubmed: 14563891 doi: 10.1093/jac/dkg446
Peterson, N. D., Rosen, B. C., Dillon, N. A. & Baughn, A. D. Uncoupling Environmental pH and Intrabacterial Acidification fromscorpio Pyrazinamide Susceptibility in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 59(12), 7320–6, https://doi.org/10.1128/AAC.00967-15 (2015).
pubmed: 26369957 pmcid: 4649215 doi: 10.1128/AAC.00967-15
Lamont, E. A. & Baughn, A. D. Impact of the host environment on the antitubercular action of pyrazinamide. EBioMedicine., 49, 374–80, https://linkinghub.elsevier.com/retrieve/pii/S2352396419306656 (2019).
Lamont, E. A, Dillon, N. A & Baughn, A. D. The Bewildering Antitubercular Action of Pyrazinamide. Microbiol Mol Biol Rev., 84(2), https://doi.org/10.1128/MMBR.00070-19 (2020).
Shi, W. et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis: a potenatial mechnism for shortening the duration of chemotrerapy. Science (80-)., 333(6049), 1630–2, http://science.sciencemag.org/content/333/6049/1630 (2012).
Yang, J. et al. Structural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamide. Mol. Microbiology. 95, 791–803 (2015).
doi: 10.1111/mmi.12892
Dillon, N. A., Peterson, N. D., Rosen, B. C. & Baughn, A. D. Pantothenate and pantetheine antagonize the antitubercular activity of pyrazinamide. Antimicrob. Agents Chemother. 58(12), 7258–63 (2014).
pubmed: 25246400 pmcid: 4249577 doi: 10.1128/AAC.04028-14
Zimhony, O., Cox, J. S., Welch, J. T., Vilchèze, C. & Jacobs, W. R. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med., 6(9), 1043–7, http://www.nature.com/articles/nm0900_1043 (2000).
Kitakawa, M. & Isono, K. An amber mutation in the gene rpsA for ribosomal protein S1 in Escherichia coli. MGG Mol Gen Genet. 185(3), 445–7, https://doi.org/10.1007/BF00334137 (1982).
pubmed: 6212755 doi: 10.1007/BF00334137
Sukhodolets, M. V. Ribosomal protein S1 promotes transcriptional cycling. RNA. Jun. 12(8), 1505–13 (2006).
doi: 10.1261/rna.2321606
Tzareva, N. V., Makhno, V. I. & Boni, I. V. Ribosome-messenger recognition in the absence of the Shine-Dalgarno interactions. FEBS Lett. Jan. 337(2), 189–94 (1994).
doi: 10.1016/0014-5793(94)80271-8
Boni, I. V., Lsaeva, D. M., Musychenko, M. L. & Tzareva, N. V. Ribosome-messenger recognition: mRNA target sites for ribosomal protein S1. Nucleic Acids Res. 19(1), 155–62, https://doi.org/10.1093/nar/19.1.155 (1991).
pubmed: 2011495 pmcid: 333546 doi: 10.1093/nar/19.1.155
McGinness, K. E. & Sauer, R. T. Ribosomal protein S1 binds mRNA and tmRNA similarly but plays distinct roles in translation of these molecules. Proc Natl Acad Sci. 101(37), 13454–9, https://doi.org/10.1073/pnas.0405521101 (2004).
pubmed: 15340139 doi: 10.1073/pnas.0405521101
Keiler, K. C. Biology of trans -Translation. Annu. Rev. Microbiol. Oct. 62(1), 133–51 (2008).
doi: 10.1146/annurev.micro.62.081307.162948
Kurita, D., Muto, A. & Himeno, H. tRNA/mRNA Mimicry by tmRNA and SmpB in Trans -Translation. J Nucleic Acids., 2011, 1–9, http://www.hindawi.com/journals/jna/2011/130581/ (2011).
Andini, N. & Nash, K. A. Expression of tmRNA in mycobacteria is increased by antimicrobial agents that target the ribosome. FEMS Microbiol Lett. 322(2), 172–9, https://doi.org/10.1111/j.1574-6968.2011.02350.x (2011).
pubmed: 21718348 pmcid: 3155661 doi: 10.1111/j.1574-6968.2011.02350.x
Saguy, M., Gillet, R., Skorski, P., Hermann-Le Denmat, S. & Felden, B. Ribosomal protein S1 influences trans-translation in vitro and in vivo. Nucleic Acids Res. Apr, 35(7), 2368–76, https://doi.org/10.1093/nar/gkm100 (2007).
doi: 10.1093/nar/gkm100
Personne, Y. & Parish, T. Mycobacterium tuberculosis possesses an unusual tmRNA rescue system. Tuberculosis., 94(1), 34–42, https://linkinghub.elsevier.com/retrieve/pii/S1472979213001674 (2014).
Dillon, N. A., Peterson, N. D., Feaga, H. A., Keiler, K. C. & Baughn, A. D. Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA. Sci Rep. 7(1), 1–8, https://doi.org/10.1038/s41598-017-06415-5 (2017).
doi: 10.1038/s41598-017-06415-5
Peñuelas-Urquides, K. et al. Comparison of gene expression profiles between pansensitive and multidrug-resistant strains of mycobacterium tuberculosis. Curr. Microbiol. 67(3), 362–71 (2013).
pubmed: 23649743 doi: 10.1007/s00284-013-0376-8
Salah, P. et al. Probing the relationship between Gram-negative and Gram-positive S1 proteins by sequence analysis. Nucleic Acids Res. Sep. 37(16), 5578–88 (2009).
doi: 10.1093/nar/gkp547
Wower, I. K., Jahan, N., Zwieb, C. & Wower, J. Ribosomal Protein S1: An Important Trans-Translational Factor. Biochem Physiol Open Access. s2., http://www.omicsgroup.org/journals/ribosomal-protein-s1-an-important-trans-translational-factor-2168-9652.S2-001.php?aid=13500 (2013).
Hellman, L. M. & Fried, M. G. Electrophoretic mobility shift assay (EMSA) for detecting protein–nucleic acid interactions. Nat Protoc., 2(8), 1849–61, http://www.nature.com/articles/nprot.2007.249 (2007).
Scheuermann, T. H., Padrick, S. B., Gardner, K. H. & Brautigam, C. A. On the acquisition and analysis of microscale thermophoresis data. Anal. Biochem. Mar. 496, 79–93 (2016).
doi: 10.1016/j.ab.2015.12.013
Lewis, E. A. & Murphy, K. P. Isothermal Titration Calorimetry. In: Protein-Ligand Interactions. New Jersey: Humana Press; p. 001–16., https://doi.org/10.1385/1-59259-912-5:001 (2005).
Duff, M. R., Jr., Grubbs, J. & Howell, E. E. Isothermal Titration Calorimetry for Measuring Macromolecule-Ligand Affinity. J Vis Exp., 7 (55), http://www.jove.com/details.php?id=2796 (2011).
Fielding, L. NMR Methods for the Determination of Protein- Ligand Dissociation Constants. Curr Top Med Chem., 3(1), 39–53, http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1568-0266&volume=3&issue=1&spage=39 . (2003).
Lucas, L. H. & Larive, C. K. Measuring ligand-protein binding using NMR diffusion experiments. Concepts Magn Reson. 20A(1), 24–41, https://doi.org/10.1002/cmr.a.10094 (2004).
doi: 10.1002/cmr.a.10094
Mayer, M. & Meyer, B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. - Int. Ed. 38(12), 1784–8 (1999).
doi: 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q
Duan, H. et al. Evaluation of the ribosomal protein S1 gene (rpsA) as a novel biomarker for mycobacterium species identification. Biomed Res Int. April (2015).
Moore, S. D. & Sauer, R. T. Ribosome rescue: tmRNA tagging activity and capacity in Escherichia coli. Mol. Microbiol. 58(2), 456–66 (2005).
pubmed: 16194232 doi: 10.1111/j.1365-2958.2005.04832.x
Karzai, A. W. & Sauer, R. T. Protein factors associated with the SsrA·SmpB tagging and ribosome rescue complex. Proc. Natl Acad. Sci. USA 98(6), 3040–4 (2001).
pubmed: 11248028 doi: 10.1073/pnas.051628298
Fan, Y. et al. Structural basis for ribosome protein S1 interaction with RNA in trans-translation of Mycobacterium tuberculosis. Biochem Biophys Res Commun. 487(2), 268–73, https://doi.org/10.1016/j.bbrc.2017.04.048 (2017).
pubmed: 28412369 doi: 10.1016/j.bbrc.2017.04.048.
Wower, I. K. Binding and cross-linking of tmRNA to ribosomal protein S1, on and off the Escherichia coli ribosome. EMBO J. 19(23), 6612–21 (2000).
pubmed: 11101533 pmcid: 305868 doi: 10.1093/emboj/19.23.6612
Connelly, P. R. et al. Enthalpy of hydrogen bond formation in a protein-ligand binding reaction. Proc Natl Acad Sci. 91(5), 1964–8, https://doi.org/10.1073/pnas.91.5.1964 (1994).
pubmed: 7510408 doi: 10.1073/pnas.91.5.1964
Steiner, T. The hydrogen bond in the solid state. Angew. Chem. - Int. Ed. 41(1), 48–76 (2002).
doi: 10.1002/1521-3773(20020104)41:1<48::AID-ANIE48>3.0.CO;2-U
Sayahi, H. et al. Analogs of the Antituberculous Agent Pyrazinamide Are Competitive Inhibitors of NADPH Binding to M. tuberculosis Fatty Acid Synthase I. Chem Biodivers. 9(11), 2582–96, https://doi.org/10.1002/cbdv.201200291 (2012).
pubmed: 23161636 doi: 10.1002/cbdv.201200291
Simons, S. O., Mulder, A., Van Ingen, J., Boeree, M. J. & Van Soolingen, D. Role of rpsA gene sequencing in diagnosis of pyrazinamide resistance. J. Clin. Microbiol. 51(1), 382 (2013).
pubmed: 23269981 pmcid: 3536190 doi: 10.1128/JCM.02739-12
Tan, Y. et al. Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in mycobacterium tuberculosis isolates from southern China. J. Clin. Microbiol. 52(1), 291–7 (2014).
pubmed: 24131688 pmcid: 3911430 doi: 10.1128/JCM.01903-13
Gu, Y. et al. Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA, rpsA, and panD gene mutations. Diagn Microbiol Infect Dis. 84(3), 207–11, https://doi.org/10.1016/j.diagmicrobio.2015.10.017. (2016).
pubmed: 26775806 doi: 10.1016/j.diagmicrobio.2015.10.017.
Xia, Q. et al. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China. Antimicrob. Agents Chemother. 59(3), 1690–5 (2015).
pubmed: 25583712 pmcid: 4325781 doi: 10.1128/AAC.04541-14
Ramirez-Busby, S. M. et al. A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis. Sci. Rep. 7(1), 1–9 (2017).
doi: 10.1038/s41598-017-03452-y
Werngren, J., Alm, E. & Mansjö, M. Non- pncA Gene-Mutated but Pyrazinamide-Resistant Mycobacterium tuberculosis: Why Is That? Land GA, editor. J. Clin. Microbiol. 2017 Jun 55(6), 1920–7, https://doi.org/10.1128/JCM.02532-16 (2017).
Klemens, S. P., Sharpe, C. A. & Cynamon, M. H. Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility. Antimicrob Agents Chemother., 40(1), 14–6, http://www.ncbi.nlm.nih.gov/pubmed/8787871 (1996).
Scorpio, A. et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother., 41(3), 540–3, http://www.ncbi.nlm.nih.gov/pubmed/9055989 (1997).
Shi, W. et al. Introducing RpsA point mutations 438A and D123A into the chromosome of mycobacterium tuberculosis confirms their role in causing resistance to pyrazinamide. Antimicrob. Agents Chemother. 63(6), 1–16 (2019).
doi: 10.1128/AAC.02681-18
Alexander, D. C. et al. Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: A role for pncA but not rpsA. J. Clin. Microbiol. 50(11), 3726–8 (2012).
pubmed: 22895038 pmcid: 3486241 doi: 10.1128/JCM.00620-12
Akhmetova, A. et al. Mutations in the pncAand rpsAgenes among 77 Mycobacterium tuberculosis isolates in Kazakhstan. Int. J. Tuberc. Lung Dis. 2015 19(2), 179–84 (2015).
doi: 10.5588/ijtld.14.0305
Sambrook and Russell. Molecular cloning: a laboratory manual. (Cold Spring Harbor LAboratory Press; 2001).
Block, H. et al. Chapter 27 Immobilized-Metal Affinity Chromatography (IMAC). A Review. Methods Enzymol. 463(C), 439–73 (2009).
pubmed: 19892187 doi: 10.1016/S0076-6879(09)63027-5
Wilkins, M. R. et al. Protein Identification and Analysis Tools in the ExPASy Server. In: 2-D Proteome Analysis Protocols. New Jersey: Humana Press; p. 531–52., https://doi.org/10.1385/1-59259-584-7:531 .
Stejskal, E. O. & Tanner, J. E. Spin Diffusion Measurements: Spin Echoes in the Presence of a Time‐Dependent Field Gradient. J Chem Phys. 42(1), 288–92, https://doi.org/10.1063/1.1695690 (1965).
doi: 10.1063/1.1695690

Auteurs

Katherine Vallejos-Sánchez (K)

Laboratorio de Bioinformática, Biología Molecular y Desarrollos Tecnológicos. Laboratorios de Investigación y Desarrollo. Facultad de Ciencias y Filosofía. Universidad Peruana Cayetano Heredia, Lima, Perú.

Juan M Lopez (JM)

Pontificia Universidad Católica del Perú, Departamento de Ciencias, Sección Química, Centro de Espectroscopía de Resonancia Magnética Nuclear (CERMN), Lima, Perú.

Ricardo Antiparra (R)

Laboratorio de Bioinformática, Biología Molecular y Desarrollos Tecnológicos. Laboratorios de Investigación y Desarrollo. Facultad de Ciencias y Filosofía. Universidad Peruana Cayetano Heredia, Lima, Perú.

Emily Toscano (E)

Laboratorio de Bioinformática, Biología Molecular y Desarrollos Tecnológicos. Laboratorios de Investigación y Desarrollo. Facultad de Ciencias y Filosofía. Universidad Peruana Cayetano Heredia, Lima, Perú.

Harry Saavedra (H)

Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD., USA.

Daniela E Kirwan (DE)

Infection and Immunity Research Institute, St George's, University of London, London, England.

L M Amzel (LM)

Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD., USA.

R H Gilman (RH)

International Health Department. Johns Hopkins School of Public Health, Baltimore, MD, USA.

Helena Maruenda (H)

Pontificia Universidad Católica del Perú, Departamento de Ciencias, Sección Química, Centro de Espectroscopía de Resonancia Magnética Nuclear (CERMN), Lima, Perú.

Patricia Sheen (P)

Laboratorio de Bioinformática, Biología Molecular y Desarrollos Tecnológicos. Laboratorios de Investigación y Desarrollo. Facultad de Ciencias y Filosofía. Universidad Peruana Cayetano Heredia, Lima, Perú.

Mirko Zimic (M)

Laboratorio de Bioinformática, Biología Molecular y Desarrollos Tecnológicos. Laboratorios de Investigación y Desarrollo. Facultad de Ciencias y Filosofía. Universidad Peruana Cayetano Heredia, Lima, Perú. mirko.zimic@upch.pe.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH